Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126894861 | 12689486 | 1 | I | 20160118 | 20160818 | 20160826 | 20160826 | EXP | US-GLAXOSMITHKLINE-US2016120258 | GLAXOSMITHKLINE | 57.71 | YR | M | Y | 0.00000 | 20160826 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126894861 | 12689486 | 1 | PS | ADVAIR DISKUS | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Respiratory (inhalation) | 1 MG, BID | UNKNOWN | 21077 | 1 | MG | INHALATION POWDER | BID | |||||
| 126894861 | 12689486 | 2 | SS | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | Oral | 75 MG, QD | UNKNOWN | 0 | 75 | MG | QD | ||||||
| 126894861 | 12689486 | 3 | SS | XARELTO | RIVAROXABAN | 1 | Oral | 20 MG, QD | UNKNOWN | 0 | 20 | MG | QD | ||||||
| 126894861 | 12689486 | 4 | C | HUMIRA | ADALIMUMAB | 1 | U | 0 | |||||||||||
| 126894861 | 12689486 | 5 | C | XARELTO | RIVAROXABAN | 1 | U | 0 | |||||||||||
| 126894861 | 12689486 | 6 | C | ATORVASTATIN | ATORVASTATIN | 1 | U | 0 | |||||||||||
| 126894861 | 12689486 | 7 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | U | 0 | |||||||||||
| 126894861 | 12689486 | 8 | C | COLESTIPOL | COLESTIPOL | 1 | U | 0 | |||||||||||
| 126894861 | 12689486 | 9 | C | DIAZEPAM. | DIAZEPAM | 1 | U | 0 | |||||||||||
| 126894861 | 12689486 | 10 | C | DIPHENOXYLATE | DIPHENOXYLATE | 1 | U | 0 | |||||||||||
| 126894861 | 12689486 | 11 | C | DULOXETINE. | DULOXETINE | 1 | U | 0 | |||||||||||
| 126894861 | 12689486 | 12 | C | FUROSEMIDE. | FUROSEMIDE | 1 | U | 0 | |||||||||||
| 126894861 | 12689486 | 13 | C | GABAPENTIN. | GABAPENTIN | 1 | U | 0 | |||||||||||
| 126894861 | 12689486 | 14 | C | OXYCODONE | OXYCODONE | 1 | U | 0 | |||||||||||
| 126894861 | 12689486 | 15 | C | TAMSULOSIN | TAMSULOSIN | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126894861 | 12689486 | 1 | Chronic obstructive pulmonary disease |
| 126894861 | 12689486 | 2 | Thrombosis |
| 126894861 | 12689486 | 3 | Thrombosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126894861 | 12689486 | HO |
| 126894861 | 12689486 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126894861 | 12689486 | Arthralgia | |
| 126894861 | 12689486 | Asthenia | |
| 126894861 | 12689486 | Blood disorder | |
| 126894861 | 12689486 | Cerebrovascular accident | |
| 126894861 | 12689486 | Crohn's disease | |
| 126894861 | 12689486 | Diarrhoea | |
| 126894861 | 12689486 | Facial paresis | |
| 126894861 | 12689486 | Fluid retention | |
| 126894861 | 12689486 | Gastrointestinal disorder | |
| 126894861 | 12689486 | Haemorrhage | |
| 126894861 | 12689486 | Haemorrhagic diathesis | |
| 126894861 | 12689486 | Hemiplegia | |
| 126894861 | 12689486 | Hip arthroplasty | |
| 126894861 | 12689486 | Muscular weakness | |
| 126894861 | 12689486 | Pain | |
| 126894861 | 12689486 | Peripheral swelling | |
| 126894861 | 12689486 | Thrombosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126894861 | 12689486 | 1 | 201511 | 0 | ||
| 126894861 | 12689486 | 2 | 201605 | 0 | ||
| 126894861 | 12689486 | 3 | 201605 | 0 |